Rennes

• A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting
  2022-502286-16-00 5 2023-10-27 Primary Generalized Tonic-Clonic Seizures
• A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting
  2023-509810-13-00 4 2023-05-13 Acute Lymphoblastic Leukemia (ALL)
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participant … Recruiting
  2025-523481-24-00 5 2026-06-24 Participants with Progressive Supranuclear Palsy Richardson Syndrome (
• DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti … Recruiting
  2024-513292-40-00 5 2026-06-15 Multiple sclerosis
• A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants. Recruiting
  2026-526411-11-00 3 2026-06-15 Not applicable for phase I study
• Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter ran … Recruiting
  2024-518018-22-00 5 2026-06-11 staphylococcal endocarditis
• OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE Recruiting
  2025-524573-16-00 6 2026-06-11 Crohn's disease
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers Recruiting
  2026-525700-10-00 1 2026-06-08 Schizophrenia
• PROlonged Corticosteroid treatment or N-ACetylcysteine for severe alcoholic hepatitis (PROCORNAC) Recruiting
  2025-522109-39-00 5 2026-05-22 Alcoholic hepatitis
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• COMMODITIES : Comparison of initial dual oral COMbination therapy to MOnotherapy in pulmonary arterial hypertension with cardiovascular como … Recruiting
  2023-509891-40-00 5 2026-04-28 Pulmonary arterial hypertension
• Efficacy of early Argipressin (arginine vasopressin) in the management of intensive care patients with norepinephrine-refractory vasoplegic … Recruiting
  2024-516639-28-00 5 2026-03-27 norepinephrine-refractory vasoplegic shock
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• A study to test whether nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis Recruiting
  2025-522383-33-00 5 2026-03-23 Pulmonary fibrosis
• Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting
  2025-522015-42-00 10 2026-02-26 Chronic Hepatitis D Infection
• A trial to test the safety and tolerability of Lu AH70212 and Lu AH69593 in healthy adults. Recruiting
  2025-522652-58-01 1 2026-02-19 Narcolepsy
• Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease ( ATTAIN-PAD ) Recruiting
  2025-523283-21-00 5 2026-02-17 Peripheral Arterial Disease
• A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections Recruiting
  2024-516216-16-00 5 2026-02-13 Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lo
• Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection via Hysteroscopy in Severe Primary Dysmenorrhea: A Prospecti … Recruiting
  2025-520638-53-00 5 2026-02-09 Severe primary dysmenorrhea
• TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat … Recruiting
  2025-521873-15-00 9 2026-02-09 Metastatic hormone-sensitive prostate cancer
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• STOP VEN-IPC 2024-001 DE-ESCALATION STUDY EVALUATING VENETOCLAX AND AZACITIDINE DISCONTINUATION IN AML RESPONDING PATIENTS Recruiting
  2024-514112-28-00 4 2026-02-04 acute myeloid leukemia

Showing 97–120 of 529 trials